Delcath Systems, Inc. (DCTH) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. Founded in 1988, Delcath specializes in regional chemotherapy systems that deliver high doses of chemotherapy directly to tumors while minimizing systemic exposure and side effects. The company’s flagship product, the Delcath Hepatic Delivery System, is designed for use in liver cancers, allowing for targeted treatment of hepatic tumors while protecting healthy tissues.
Delcath’s proprietary technology involves a process called percutaneous hepatic perfusion (PHP), which isolates the liver and delivers high concentrations of chemotherapy directly to the tumor. This innovative approach aims to improve therapeutic outcomes for patients with conditions such as metastatic melanoma, hepatocellular carcinoma, and other liver malignancies. The company is actively engaged in clinical trials to further evaluate the safety and efficacy of its therapies and to explore new indications for its technology.
The main drivers of growth for Delcath Systems include the increasing prevalence of liver cancer and the rising demand for effective, targeted treatment options. As more healthcare providers and patients seek alternatives to traditional systemic chemotherapy, Delcath’s innovative approach positions it well in the oncology market. Additionally, the company’s focus on research and development, coupled with strategic partnerships and collaborations, enhances its ability to bring new therapies to market and expand its product pipeline.
Click The Image For Current Live Chart
Backtesting a stock can provide investors with critical statistical data. These results give you an informed perspective on how a stock trades within your chosen buying and selling method of analysis. The definition of trade expectancy is defined as: trade expectancy = (probability of win * average win) – (probability of loss * average loss). If the calculation returns a positive number, a trader should make money over time.
The average percentage gained on positive, money making trades was 38.7%. While the average percent loss on money losing trades was 7.03%.
Trade expectancy includes both winners and losers. Trade expectancy is displayed as a percentage. This backtest displays the dollar value, percentage, annual trade expectancy, and annual percent. Annual expectancy is the trade expectancy percentage multiplied by the number of trades per year.
The Trade expectancy % for DCTH over the past year is 27.27%. The number of trades generated per year was 4 giving an Annual Trade Expectancy of 109.07%
The average days in a trade is 84 and the average days between trades is 21.
With any method of analysis that uses past performance, it can be said that past performance is not indication of future performance. What is does provide is a probabilistic look at a stock’s price activity characteristics over time.
Click To Download Report and Backtest Data 